Pham Quang X sold 3,298 shares of Cadrenal Therapeutics, Inc. at $5.28 for −$17.4k on May 12, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
CEO and Chairman
CEO and Chairman
Filed May 29, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$17,413.44Shares × reported price
Shares traded
3,298Common Stock
Price per share
$5.28Reported price. Read footnotes for ranges.
% of reported position traded
1.75%This security and ownership context
Holdings after
185,150Direct
Trade date
May 12, 2026Sell
Filed
May 29, 2026, 4:30 PM ET17-day reporting delay
Accession
0001213900-26-062862Code S · Transaction 95496
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 188,448 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 11, 2026Sell6,476$5.76−$37,301.76Trade 95495
May 28, 2026Sell2,989$4.93−$14,735.77Trade 95498
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 17 calendar days after the transaction date.

CVKD price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CVKD · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Jun 5, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.47 through $6.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The total shares reported as directly owned in Column 5 takes into account subsequent transactions effected by the Reporting Person and reported on a Form 4 filed on May 26, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 through $5.535. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 through $5.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6: On May 26, 2026, the Reporting Person filed a Form 4 which inadvertently understated in Column 5 the number of shares indirectly owned by the Reporting Person. This inadvertent understatement has been corrected in this filing. F7: Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.